-+ 0.00%
-+ 0.00%
-+ 0.00%

Oppenheimer Maintains Outperform on Opus Genetics, Raises Price Target to $20

Benzinga·09/09/2026 20:09:35
语音播报
Oppenheimer analyst Andreas Argyrides maintains Opus Genetics (NASDAQ:IRD) with a Outperform and raises the price target from $10 to $20.